[A modular approach to in vivo gene therapy]

Bertrand Jordan1

  • 1Biologiste, généticien et immunologiste, Président d'Aprogène (Association pour la promotion de la Génomique), 13007 Marseille, France.

Medecine Sciences : M/S
|September 20, 2024
PubMed
Summary

Gene editing successfully inactivated a harmful gene in vivo, showing excellent results in a small trial. This modular CRISPR-Cas9 gene therapy approach, using a modified guide RNA, offers potential for treating various genetic diseases.